Advances in Process Liquid Outsourcing for CDMOs

One of the most important (but less talked about) changes in this area is the increasing use of process liquid outsourcing, especially for buffers, media solutions and other GMP grade liquid preparations. Once thought of as a purely in-house operational decision, it is becoming a strategic outsourcing decision. 

This article examines why and how the CDMOs are turning to their external partners for process liquid manufacturing and what impact it will have on the future of biopharma manufacturing.

Why CDMOs Are Moving Toward Process Liquid Outsourcing

There are two reasons why CDMOs are moving towards process liquid outsourcing.

In such a competitive landscape, CDMOs must work efficiently, scale up, and meet regulations if they are to be successful. In this background, some CDMOs are re-evaluating their “in-house” preparation models, especially with the increase in pipelines and the increasing need for manufacturing.

This change is being influenced by several important aspects:

1. Enhance cost pressure and operational efficiency.

There is a need for dedicated infrastructure, trained people, quality control, and validation procedures for in-house preparation of process liquids. These add significant overhead costs.

By outsourcing, CDMOs can:

• Reduce facility and equipment utilization costs 
• Reduce labour intensive preparation activities 
• Reduce production floor space for higher value operations. 
• Improve batch turnaround time 

Outsourcing allows CDMOs to redirect internal resources toward core manufacturing and innovation activities rather than routine solution preparation.Explore how advanced process liquid outsourcing solutions are enabling next-generation CDMO performance and efficiency.

Explore how advanced process liquid outsourcing solutions are enabling next-generation CDMO performance and efficiency.  Learn more through the Thermo Fisher whitepaper on advances in process liquid outsourcing for CDMOs.

2. Demand for Greater Manufacturing Scalability

Biologics, such as monoclonal antibodies, vaccines and more advanced therapies, have been growing at a breath-taking pace and have put a strain on manufacturing capacity.

The larger the scale of production, the greater the amount of process liquids needed. This can quickly become a pain in the arse if done in-house.

External suppliers specializing in process liquids offer:

• High-volume production capabilities 
• Modular supply models adjusted to the changes in demand 
• Minimized delays in production because of internal factors 

For CDMOs with several client projects, this is an important aspect of scalability.

3. Strengthening GMP Compliance and Standardization

One of the most important things in biopharmaceutical manufacturing is the regulatory compliance. Process liquids need to be prepared, validated and documented on a regular basis.

Outsourcing partners often operate dedicated GMP facilities optimized for:

• Batch-to-batch consistency 
• The rigor of quality control testing
• Standardized formulation protocols 
• Full traceability and documentation 

This helps to lower the burden of compliance regulations on CDMOs and lowers the chance of any deviations in compliance being detected during an audit.

4. Reducing Contamination and Quality Risks

Preparations of process liquids in-house add extra handling requirements, which can lead to contamination or variability.

These risks can be reduced by outsourcing GMP certified production, which involves: 

• Minimizing manual handling in manufacturing environments 
• Using controlled, dedicated production systems 
• Valuated cleaning and sterilization processes are ensured. 
• Improving environmental control standards 

For CDMOs handling sensitive biologics, this risk reduction is a significant operational advantage.

The Rise of Outsourced GMP Buffer Production

One of the most prominent segments within process liquid outsourcing is GMP buffer production.

Buffers are important in maintaining the stability of the pH and in allowing the downstream purification processes like chromatography and filtration. Variations in buffer composition can have an impact on the yield and purity of the product.

Traditionally, CDMOs prepared buffers in-house. This model, however, is now largely giving way to an outsourced system because of:

• The complexity of buffer preparation at scale 
• The need for validated and reproducible formulations 
• Rising QC workload associated with buffer verification 

Outsourced GMP buffer production enables CDMOs to achieve:

• Higher consistency across batches 
• Reduced validation burden 
• Improved reproducibility in downstream processes 
• Better resource allocation within manufacturing facilities 

As pipelines continue to get more complicated in the biologic arena, this trend will only continue.

Custom Buffer Manufacturing: Flexible Bioprocessing

While standardized buffers are used in many biopharmaceutical processes, there are a number of processes that require custom buffer formulations for the specific molecule, step, or purification method.

Custom buffer manufacturing allows CDMOs to:

• Adjust buffer composition as per the requirement of a particular molecule. 
• Control and optimize the pH and conductivity at which the process works and the ionic strength of the solution. 
• Support diverse client pipelines without internal reconfiguration 
• Improve process robustness and yield consistency 

This is important especially in:

• Monoclonal antibody production 
• Vaccine development 
• Cell and gene therapy workflows 

As bioprocessing becomes more specialized, demand for custom buffer solutions is expected to increase significantly.

Challenges in Process Liquid Outsourcing

While outsourcing process liquids presents benefits, it also has its drawbacks. CDMOs need to be mindful of external relationships, to ensure continuity and compliance.

1. Supply Chain Dependency

Using an external supplier lends itself to a number of potential risks, including:

• Delivery delays 
• Supplier capacity limitations 
• Disruption caused by geological or logistics issues. 

CDMOs must be in a position to have solid supply contracts and contingencies.

2. Validation and Technology Transfer Complexity

It is important to thoroughly test each process liquid formulation to ensure that it fits into existing manufacturing processes.

Challenges include:

• Evaluating and assuring the equivalence of in-house vs. outsourced formulations 
• Handling documentation for regulatory applications 
• Coordinating tech transfer between organizations 

3. Regulatory Alignment across Regions

Global CDMOs have a presence in various regulatory zones such as FDA, EMA, and regional authorities.

The outsourced partners must adhere to:

• Regional GMP standards 
• Documentation and audit requirements 
• Export/import regulations for controlled materials 

4. Storage and Stability Considerations

Process liquids often require controlled storage conditions, including:

• Temperature regulation 
• Shelf-life management 
• Sterility maintenance 

Any deviation in storage conditions can impact product integrity.

Process Liquid Outsourcing within Broader CDMO Strategies

Process liquid outsourcing is not an isolated trend—it is part of a broader shift toward biopharma manufacturing outsourcing strategies.

CDMOs are increasingly adopting integrated outsourcing models that include:

• Raw material sourcing 
• Buffer and media preparation 
• Fill-finish operations 
• Analytical testing services 

This complete outsourcing solution can assist you to:

• Faster time-to-market 
• Reduced operational complexity 
• Improved capital efficiency 
• Greater focus on core R&D and process innovation 

Consequently, outsourcing has become an integral part of today's CDMO networks.

What's to come: the Industry's future?

The subsequent key trends are likely to shape the process liquid outsourcing market in the future:

1. Automation and Digitalization

• Automated buffer preparation systems 
• Digital batch tracking and compliance reporting 
• Access to MES and ERP systems 

2. Single-Use Technology Integration

• Reduced cleaning requirements 
• Lower contamination risk 
• Faster changeover between batches 

3. Real-Time Quality Monitoring

• Inline sensors for pH and conductivity 
• AI-driven process control systems 
• Predictive quality analytics 

4. Growth of global outsourcing networks

• The region's growth potential in the APAC and emerging markets
• Regional manufacturing hubs for faster supply 
• Diversified supplier ecosystems to reduce risk 

Conclusion

Process liquid outsourcing is quickly changing from a cost-saving strategy to a strategy that enables scalable and compliant biopharmaceutical manufacturing. It is a way for CDMOs to gain more efficiency in their operations, meet regulatory requirements and maintain greater flexibility during production.

The increasing complexity of biologics pipelines will only lead to a growing demand for outsourced GMP buffer production and custom buffer manufacturing. Today's organizations implementing integrated outsourcing practices will be more ready to face manufacturing challenges of tomorrow.